SSY Group Gains Approval for New Pharmaceutical Products in China

An update from SSY Group ( (HK:2005) ) is now available.

SSY Group Limited has received approval from China’s National Medical Products Administration for the production and registration of two drugs: Dronedarone Hydrochloride Tablets and Gabexate Mesylate for Injection. These approvals mark significant advancements in the company’s product offerings, with Dronedarone Hydrochloride targeting atrial fibrillation and Gabexate Mesylate addressing acute pancreatitis. This development enhances SSY Group’s position in the pharmaceutical market, potentially benefiting stakeholders by expanding the company’s portfolio and market reach.

The most recent analyst rating on (HK:2005) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.

More about SSY Group

SSY Group Limited operates in the pharmaceutical industry, focusing on the development and production of chemical drugs. The company is engaged in the creation of medications aimed at treating various medical conditions, with a market focus on China.

Average Trading Volume: 7,138,901

Technical Sentiment Signal: Sell

Current Market Cap: HK$8.71B

For a thorough assessment of 2005 stock, go to TipRanks’ Stock Analysis page.